

Oncology Today with Dr Neil Love: Optimizing the Role of CAR T-Cell Therapy in the Management of Multiple Myeloma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **What was the study design of the CARTITUDE-4 trial for multiple myeloma (MM)?**
 - a. Single-arm trial of ciltacabtagene autoleucl (cilta-cel) for patients who have received 1 to 3 prior lines of therapy
 - b. Single-arm trial of cilta-cel for patients who have received 3 or more prior lines of therapy
 - c. Randomized trial of cilta-cel versus standard treatment for patients who have received three or more prior lines of therapy
 - d. Randomized trial of cilta-cel versus standard treatment for patients who have received 1 to 3 prior lines of therapy

2. **What was the reported long-term overall survival (OS) finding with cilta-cel in the CARTITUDE-4 study?**
 - a. Inferior OS outcomes with cilta-cel versus standard treatment
 - b. No significant difference in OS with cilta-cel versus standard treatment
 - c. A statistically significant improvement in OS with cilta-cel versus standard treatment

3. **What was the approximate 30-month progression-free survival rate observed with cilta-cel in the CARTITUDE-4 study?**
 - a. 30%
 - b. 41%
 - c. 68%
 - d. 85%

4. **What is the mechanism of action of anitocabtagene autoleucl for relapsed/refractory (R/R) MM?**
 - a. CD19-targeted chimeric antigen receptor (CAR) T-cell therapy
 - b. BCMA-targeted CAR T-cell therapy
 - c. GPRC5D-targeted CAR T-cell therapy

5. **What is the mechanism of action of arlocabtagene autoleucl for R/R MM?**
 - a. CD19-targeted CAR T-cell therapy
 - b. BCMA-targeted CAR T-cell therapy
 - c. GPRC5D-targeted CAR T-cell therapy